Bankole A. Johnson
YOU?
Author Swipe
View article: Evidence of Coherent Elastic Neutrino-Nucleus Scattering with COHERENT’s Germanium Array
Evidence of Coherent Elastic Neutrino-Nucleus Scattering with COHERENT’s Germanium Array Open
We report the first detection of coherent elastic neutrino-nucleus scattering (CEvNS) on natural germanium, measured at the Spallation Neutron Source at Oak Ridge National Laboratory. The Ge-Mini detector of the COHERENT collaboration empl…
View article: Low-dose ondansetron: A candidate prospective precision medicine to treat alcohol use disorder endophenotypes
Low-dose ondansetron: A candidate prospective precision medicine to treat alcohol use disorder endophenotypes Open
In this Phase 3 clinical trial, AD04 was shown to be a promising treatment for currently drinking heavy drinking individuals with AUD who also possess a specific genotypic profile in the serotonin transporter and serotonin-3AB receptor com…
View article: Safety and compliance of long-term low-dose ondansetron in alcohol use disorder treatment.
Safety and compliance of long-term low-dose ondansetron in alcohol use disorder treatment. Open
Low-dose AD04 has the potential to be a safe treatment option for subjects with AUD and ALD, indicating the need for an RCT for this specific cohort. Such a trial would pave the way for the design of a precision treatment for combined AUD …
View article: A critical scientific evaluation of a purportedly negative data report – response to Seneviratne et al. 2022
A critical scientific evaluation of a purportedly negative data report – response to Seneviratne et al. 2022 Open
A core principle in the pursuit of scientific knowledge is that science is self-correcting and that important results should be replicable. Hypotheses need to be reinforced, adjusted, or rejected when novel results are obtained. Replicatio…
View article: A Phase 3 Randomized Precision Medicine Clinical Trial Using Low-Dose Ondansetron (a 5-HT3 Antagonist) to Treat Alcohol Use Disorder
A Phase 3 Randomized Precision Medicine Clinical Trial Using Low-Dose Ondansetron (a 5-HT3 Antagonist) to Treat Alcohol Use Disorder Open
Genetic predisposition may determine treatment response in alcohol use disorder (AUD). This 6-month, double-blind, randomized trial assessed ondansetron (0.33 mg twice daily; AD04) in genotype-specific AUD subjects stratified by drinking e…
View article: A Prospective Precision Medicine Phase 3 Clinical Trial of Low-dose Ondansetron (a 5-ht3 Antagonist) to Treat Heavy and Very Heavy Drinkers With Alcohol Use Disorder
A Prospective Precision Medicine Phase 3 Clinical Trial of Low-dose Ondansetron (a 5-ht3 Antagonist) to Treat Heavy and Very Heavy Drinkers With Alcohol Use Disorder Open
This 6-month, double-blind, randomized, Phase-3 clinical trial in Alcohol Use Disorder (AUD; n = 303) tested ondansetron 0.33 mg/twice daily (AD04) vs placebo in reducing the Percentage of Heavy Drinking Days (PHDD) among a genetic subgrou…
View article: A Prospective Pharmacogenetic Phase 3 Clinical Trial of Low-Dose Ondansetron (A 5-HT3 Antagonist) to Treat Heavy and Very Heavy Drinkers With Alcohol Use Disorder
A Prospective Pharmacogenetic Phase 3 Clinical Trial of Low-Dose Ondansetron (A 5-HT3 Antagonist) to Treat Heavy and Very Heavy Drinkers With Alcohol Use Disorder Open
This 6-month, double-blind, randomized, Phase-3 clinical trial of individuals with Alcohol Use Disorder (AUD) assessed the efficacy of ondansetron 0.33 mg/twice daily (AD04) vs placebo at reducing the Percentage of Heavy Drinking Days (PHD…
View article: Validation of serotonin transporter <scp>mRNA</scp> as a quantitative biomarker of heavy drinking and its comparison to ethyl glucuronide/ethyl sulfate: A randomized, double‐blind, crossover trial
Validation of serotonin transporter <span>mRNA</span> as a quantitative biomarker of heavy drinking and its comparison to ethyl glucuronide/ethyl sulfate: A randomized, double‐blind, crossover trial Open
Background The serotonin transporter (SERT) mRNA was previously reported to be a quantitative and pathophysiology‐based biomarker of heavy drinking in 5HTTLPR:LL genotype‐carriers treated with ondansetron. Here, we validated the potential …
View article: Statistical Analysis of Zero-Inflated Nonnegative Continuous Data: A Review
Statistical Analysis of Zero-Inflated Nonnegative Continuous Data: A Review Open
Zero-inflated nonnegative continuous (or semicontinuous) data arise frequently in biomedical, economical, and ecological studies. Examples include substance abuse, medical costs, medical care utilization, biomarkers (e.g., CD4 cell counts,…
View article: Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials
Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials Open
ClinicalTrials.gov identifiers: NCT00006206; NCT01146613; NCT00210925.